Capital Impact Advisors LLC decreased its position in TherapeuticsMD Inc (NASDAQ:TXMD) by 27.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 113,811 shares of the company’s stock after selling 43,600 shares during the period. Capital Impact Advisors LLC owned approximately 0.06% of TherapeuticsMD worth $600,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp boosted its position in TherapeuticsMD by 6.9% in the first quarter. State Street Corp now owns 3,903,491 shares of the company’s stock worth $28,105,000 after buying an additional 253,237 shares during the period. Oppenheimer & Co. Inc. boosted its position in TherapeuticsMD by 94.5% in the first quarter. Oppenheimer & Co. Inc. now owns 41,466 shares of the company’s stock worth $298,000 after buying an additional 20,148 shares during the period. Schwab Charles Investment Management Inc. boosted its position in TherapeuticsMD by 10.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 626,312 shares of the company’s stock worth $4,510,000 after buying an additional 60,229 shares during the period. Geode Capital Management LLC boosted its position in TherapeuticsMD by 10.1% in the first quarter. Geode Capital Management LLC now owns 1,279,601 shares of the company’s stock worth $9,213,000 after buying an additional 117,660 shares during the period. Finally, Vanguard Group Inc. boosted its position in TherapeuticsMD by 5.6% in the first quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock worth $70,574,000 after buying an additional 515,992 shares during the period.
Shares of TherapeuticsMD Inc (NASDAQ:TXMD) traded up 2.06% during trading on Wednesday, hitting $5.94. The stock had a trading volume of 3,342,849 shares. The firm has a 50-day moving average of $5.44 and a 200 day moving average of $5.53. TherapeuticsMD Inc has a 1-year low of $3.50 and a 1-year high of $8.30. The company’s market capitalization is $1.21 billion.
TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. The company had revenue of $4.25 million during the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative net margin of 530.84% and a negative return on equity of 71.36%. The firm’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.11) earnings per share. Equities research analysts predict that TherapeuticsMD Inc will post ($0.42) earnings per share for the current fiscal year.
A number of research firms have issued reports on TXMD. Cantor Fitzgerald reiterated an “overweight” rating and set a $33.00 target price on shares of TherapeuticsMD in a report on Tuesday. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $10.00 target price on shares of TherapeuticsMD in a report on Friday, July 21st. Deutsche Bank AG set a $10.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a report on Friday, August 11th. Jefferies Group LLC reiterated a “buy” rating and set a $15.00 target price on shares of TherapeuticsMD in a report on Friday, August 11th. Finally, Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $16.14.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with our FREE daily email newsletter.